Search results for "PSORIASIS"

Incidence of onychomycosis among psoriatic patients with nail involvement: a descriptive study

2013

Comment on “ COVID ‐19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action”

2020

Differential Effects of Biologics on Psoriasis-Related Vascular Inflammation and Risk of Thrombosis

2020

Programa Estatal de I+D+i Orientada a los Retos de la Sociedad from Ministerio de Ciencia, Innovación y Universidades and European Regional Development Fund (Spain) [RTI2018-094436-B-I00]; Ministerio de Sanidad y Consumo CIBERehd (Spain) [CB06/04/0071]; Generalitat Valenciana (Spain) [PROMETEO/2018/141]; Proyectos Grupos Emergentes [GV/2019/043]; and Universidad Europea (Spain) (2018/UEM32 and 2019/UEM29]. 8.551 JCR (2020) Q1, 4/69 Dermatology 1.951 SJR (2020) Q1, 54/438 Biochemistry No data IDR 2020 UEV

Importance of HLA-DR+ and CD1a+ Epidermal Cells for Cytokine Production in Psoriasis

1995

Psoriasis is an inflammatory skin disease characterised by marked hyperproliferation of keratinocytes in association with vascular expansion, leukocyte infiltration and lymphocyte activation1. Cytokines are thought to play a pivotal role in the pathogenesis. It is speculated that a dysregulation of the cytokine network involving tumor-necrosis-factor-a (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL-8) might be the basic mechanism of the psoriatic inflammatory response2. TNF-α is the prototype of a proinflammatory peptide exerting immunomodulatory effects. IL-6 is a multifunctional cytokine with a broad range of biological functions in both acute and chronic inflammatory reactions. IL-8…

Anti-inflammatory Therapies for Cardiovascular Disease: Signaling Pathways and Mechanisms

2019

Cardiovascular diseases (CVD) are the clinical manifestation of atherosclerosis, a chronic inflammatory disease promoted by several risk factors such as dyslipidemia, type 2 diabetes mellitus, hypertension, and smoking. Acute CVD events are the result of an unresolved inflammatory chronic state that promotes the rupture of unstable plaque lesions. Of note, the existing intensive therapies modify risk factors but do not prevent life-threatening recurrent ischemic events in high-risk patients, who have a residual inflammatory risk displayed by increased C-reactive protein (CRP) levels. Better understanding of the role of innate and adaptive immunity in plaque development and rupture has led t…

Letter: psoriasiform eruption during vedolizumab therapy

2019

Tissue inflammatory biomarkers in chronic plaque psoriasis: Exploring lesional versus non‐lesional skin relative expression and possible clinical cor…

2019

An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis

2015

Background There is an unmet need for long-term, real-life data on the effect of a drug-free interval between treatment cycles in patients with plaque psoriasis being treated with etanercept, which is licensed for intermittent and continuous treatment. Objective The aim of this study was to determine the average duration of the drug-free interval between etanercept treatment cycles in patients with plaque psoriasis. Methods This was a non-interventional, open-label, multicentre, prospective study in patients for whom the decision had already been made to initiate treatment with etanercept during routine practice in German centres. Clinical outcomes were documented over 36 months with study …

Types, triggers and treatment strategies of psoriasis

2013

Psoriasis is a common chronic, immune mediated, inflammatory disease,characterized by periods of exacerbation and remission. Patients with psoriasis have asignificantly impaired quality of life; the disease is associated with substantial burden interms of disability or psychosocial stigmatization. Moreover, in a percentage of patientsthat varies between 5% and 42%, depending on the population studied, psoriatic arthritismay occur.Psoriasis is found worldwide but the prevalence varies among different ethnicgroups. It has a strong genetic component but environmental factors such as ß-haemolyticstreptococcal infection, HIV, stress, and drugs, including ß blockers, antimalarials andlithium can …

Nanoliposomas de baicalina y berberina en el tratamiento de afecciones cutáneas

2020

Las enfermedades cutáneas afectan a un gran número de personas. Entre ellas destacan la psoriasis, una enfermedad crónica inflamatoria, y el vitíligo, caracterizada por la despigmentación gradual de la piel. Asimismo, la alopecia representa una de las patologías con mayor impacto sobre la calidad de vida de los pacientes. Las tres tienen en común la ausencia de un tratamiento eficaz. Una de las posibles estrategias terapéuticas que pueden contribuir a resolver este problema sería la administración por vía tópica, ya que presenta una serie de ventajas frente a otras vías. En la presente Tesis Doctoral se propone la administración por vía tópica de productos naturales como coadyuvantes en el …